# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN-TD
- Date: 1953-04-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week follow-up; endocrinology consultation and scrotal ultrasound today. **S**

## History of present illness

Mr. Turing returns two weeks after his first visit, five weeks after the last estrogen injection. He saw Dr. Montrose-Adeyemi of endocrinology this morning and had a scrotal ultrasound, which was normal. His breasts are still tender against his shirt, with no change in size, and he has had no nipple discharge. Libido and morning erections are still absent. He has had two sessions with the clinic psychologist and found them easier than he expected; they have begun with what was done to him rather than with his sexuality, which he says he has never regarded as the problem. He sleeps five to six hours and has run twice this week, alone. He has had no suicidal thoughts and keeps his safety plan on his phone. He takes cholecalciferol daily. **S**

| Element | Detail |
|---|---|
| Breasts | Still tender; no change in size; no discharge |
| Sexual function | Libido and morning erections still absent |
| Psychotherapy | Two sessions with the clinic psychologist |
| Sleep and activity | Five to six hours; ran twice this week |
| Safety | No suicidal thoughts since intake; safety plan on his phone |
| PHQ-9 | 14, down from 15 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Breast | Positive | Tender breast tissue on both sides; no discharge or new lump |
| Genitourinary | Positive | Low libido and no morning erections; no testicular pain or swelling |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Low mood and interest, poor sleep; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 71 kg; BMI 22.4 kg/m². All vital signs are synthetic.

PHQ-9: 14; Estradiol: 46 pg/mL (high); LH: 0.9 m[IU]/mL (low). All results are synthetic.

## Change since baseline

- PHQ-9: 15 at baseline, 14 at this visit **S**
- Estradiol: 148 pg/mL (high) at baseline, 46 pg/mL (high) at this visit **S**
- LH: 0.3 m[IU]/mL (low) at baseline, 0.9 m[IU]/mL (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tall, lean, tired |
| Breast | Examined with his agreement and a chaperone offered and declined: firm, tender, rubbery disc of glandular tissue about 4 cm across behind each nipple, centered and symmetric; no discrete or eccentric mass, skin change, nipple discharge, or axillary nodes |
| Genitourinary | Examined with his agreement: testes soft and slightly small, without masses, as the ultrasound confirmed |
| Mental status | Alert and cooperative; mood "still flat"; affect constricted but brightens on his work; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bilateral gynecomastia from exogenous estrogen** (N62). Typical bilateral gynecomastia on examination, so breast imaging is not needed. Endocrinology agrees that the estrogen explains it: hCG and AFP are normal and the scrotal ultrasound shows no mass. Estradiol is falling (46 pg/mL). **S**
   - Watchful waiting; no tamoxifen or other drug, as Dr. Montrose-Adeyemi advised.
   - A compression shirt for running if he wishes.
2. **Drug-induced hypogonadotropic hypogonadism** (E23.1). LH still suppressed at 0.9 mIU/mL five weeks after the last injection; recovery is expected over two to six months. **S**
   - No testosterone therapy while the axis recovers.
   - Testosterone, estradiol, LH, FSH, prolactin, and hemoglobin in six weeks.
3. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 14, down from 15, two weeks into psychotherapy. No past mania or hypomania. Suicide risk remains low, with no ideation since intake and protective factors unchanged. **S**
   - Continue weekly psychotherapy; review the antidepressant question at eight weeks if the PHQ-9 has not fallen by half.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Firm, tender glandular tissue about 4 cm behind each nipple; symmetric; no discrete mass, skin change, discharge, or nodes |
| Imaging | Breast ultrasound or mammography | Only if the examination is equivocal or a discrete mass is felt | Not indicated | Typical bilateral, centered gynecomastia on examination |
| Imaging | Scrotal ultrasound | Once, in the gynecomastia workup | Completed today | Testes about 15 mL each, homogeneous; no mass; no varicocele |
| Laboratory | Estradiol and LH while the estrogen clears | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Estradiol 46 pg/mL, down from 148; LH 0.9 mIU/mL, still suppressed |
| Laboratory | hCG, AFP, liver, kidney, and thyroid tests | Once, at the initial workup | Up to date | All normal at intake two weeks ago |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Referral | Endocrinology consultation | For gynecomastia with abnormal hormone results | Completed today | Seen today; drug-induced cause confirmed; recovery monitoring agreed |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 14, down from 15 at intake |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: on his phone, with 988 and the clinic number |
| Survey | Bipolar screen at the initial workup | Once, at the initial depression workup | Completed today | Interview found no past manic or hypomanic episode and no family history known to him; no Mood Disorder Questionnaire score is recorded |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Two sessions with a gay-affirming psychologist; sleep five to six hours; two runs alone |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |

## Goal progress

- Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy. In progress; target 1953-08-04. **S**
- Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him. In progress; target 1953-10-06. **S**
- Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5). In progress; target 1953-10-06. **S**
- Back to running about 40 km a week and changing at his club again. In progress; target 1953-10-06. **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Review in six weeks with hormone tests and PHQ-9. **S**
- Next scheduled visit 1953-06-09: eight-week review of hormone recovery and depression treatment. **S**
